Inhibition of SHP-2 promotes radiosensitivity in glioma

Sun,Quanye; Mu,Luyan; Qiao,Wanchen; Li,Hui; Tang,Jiabin; Wang,Ce; Hu,Wei; Zhao,Tianshu; Dong,Baijing; Song,Yuwen; Liu,Xiaoqian

doi:10.3892/mmr.2015.3829

Inhibition of SHP-2 promotes radiosensitivity in glioma

Authors:
- Quanye Sun
- Luyan Mu
- Wanchen Qiao
- Hui Li
- Jiabin Tang
- Ce Wang
- Wei Hu
- Tianshu Zhao
- Baijing Dong
- Yuwen Song
- Xiaoqian Liu
View Affiliations

Affiliations: Department of Neurosurgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: May 25, 2015 https://doi.org/10.3892/mmr.2015.3829
Pages: 3563-3568

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a phosphatase, SHP-2 has been identified to be involved in regulating several cell functions, including growth, division, adhesion and motility. Therefore, SHP‑2 may affect the response of glioma to radiotherapy, such as via enhancing angiogenesis. The present study aimed to investigate the function of SHP‑2, a protein tyrosine phosphatase, in the radiosensitivity of glioma. U251, U87 and SHG44 glioma cell lines were transfected with small interfering (si)RNA against SHP‑2 and cell proliferation was assessed using a cell counting kit 8 assay, cell apoptosis was assessed by fluorescence‑activated cell sorting and immunoblotting, cell invasion was determined by an invasion assay, and the vasculogenic mimicry capacity was assessed by a tube formation assay. SHP‑2 siRNA transfection reduced the proliferation and increased apoptosis in the glioma cell lines. Downregulation of SHP‑2 suppressed glioma cell invasion and vasculogenic mimicry. These results demonstrated that no significant difference was observed between glioma tissues and normal brain tissues, however, silencing of SHP‑2 inhibited cell proliferation, invasion and vasculogenic mimicry in the glioma cell lines. SHP‑2 may be a novel therapeutic target for glioma.

View Figures

View References

1	Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
2	Kim JH, Bae Kim Y, Han JH, et al: Pathologic diagnosis of recurrent glioblastoma: morphologic, immunohistochemical and molecular analysis of 20 paired cases. Am J Surg Pathol. 36:620–628. 2012. View Article : Google Scholar : PubMed/NCBI
3	Janbazian L, Karamchandani J and Das S: Mouse models of glioblastoma: lessons learned and questions to be answered. J Neurooncol. 118:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
4	Matozaki T, Murata Y, Saito Y, et al: Protein tyrosinephosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 100:1786–1793. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zheng H, Alter S and Qu CK: SHP-2 tyrosine phosphatase in human diseases. Int J Clin Exp Med. 2:17–25. 2009.PubMed/NCBI
6	Bentire-Alj M, Paez JG, David FS, et al: Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 64:8816–8820. 2004. View Article : Google Scholar
7	Zhan Y, Counelis GJ and O'Rourke DM: The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Exp Cell Res. 315:2343–2357. 2009. View Article : Google Scholar : PubMed/NCBI
8	Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
9	Maddirela DR, Kesanakurti D, Gujrati M, et al: MMP-2 suppression abrogates irradiation-induced microtubule formation in endothelial cells by inhibiting αvβ3-mediated SDF-1/CXCR4 signaling. Int J Oncol. 42:1279–1288. 2013.PubMed/NCBI
10	Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plusconcomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
11	Kargiotis O, Geka A, Rao JS, et al: Review effects of irradiation on tumor cell survival, invasion and angiogenesis. J Neurooncol. 100:323–338. 2010. View Article : Google Scholar : PubMed/NCBI
12	Prise KM, Schettino G, Folkard M, et al: Review new insights on cell death from radiation exposure. Lancet Oncol. 6:520–528. 2005. View Article : Google Scholar : PubMed/NCBI
13	Beal K, Abrey LE and Gutin PH: Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol. 6:22011. View Article : Google Scholar : PubMed/NCBI
14	Hands JR, Abel P, Ashton K, et al: Investigating the rapid diagnosis of gliomas from serum samples using infrared spectroscopy and cytokine and angiogenesis factors. Anal Bioanal Chem. 405:7347–7355. 2013. View Article : Google Scholar : PubMed/NCBI
15	Brem S, Cotran R and Folkman J: Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst. 48:347–356. 1972.PubMed/NCBI
16	Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine formetastatic pancreatic cancer. N Engl J Med. 364:1817–25. 2011. View Article : Google Scholar : PubMed/NCBI
17	Milanović D, Firat E, Grosu AL, et al: Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990. Radiat Oncol. 28:422013. View Article : Google Scholar
18	Hardee ME and Zagzag D: Mechanisms of glioma-associated neovascularization. Am J Pathol. 181:1126–1141. 2012. View Article : Google Scholar : PubMed/NCBI
19	Holash J, Maisonpierre PC, Compton D, et al: Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science. 284:1994–1998. 1999. View Article : Google Scholar : PubMed/NCBI
20	Zagzag D, Amirnovin R, Greco MA, et al: Vascular apoptosis andinvolution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest. 80:837–849. 2000. View Article : Google Scholar : PubMed/NCBI
21	Lamszus K, Ulbricht U, Matschke J, et al: Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity and VEGF-A. Clin Cancer Res. 9:1399–1405. 2003.PubMed/NCBI
22	Reiss Y, Machein MR and Plate KH: The role of angiopoietins during angiogenesis in gliomas. Brain Pathol. 15:311–17. 2005. View Article : Google Scholar
23	Rong Y, Durden DL, Van Meir EG, et al: 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia and angiogenesis. J Neuropathol Exp Neurol. 65:529–39. 2006. View Article : Google Scholar : PubMed/NCBI
24	Norden AD, Young GS, Setayesh K, et al: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity and patterns of recurrence. Neurology. 70:779–87. 2008. View Article : Google Scholar : PubMed/NCBI
25	Narayana A, Kelly P, Golfinos J, et al: Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 110:173–80. 2009. View Article : Google Scholar
26	Freeman RM Jr, Plutzky J and Neel BG: Identification of a human srchomology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. Proc Natl Acad Sci USA. 89:11239–11243. 1992. View Article : Google Scholar
27	Barr AJ: Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med Chem. 2:1563–1576. 2010. View Article : Google Scholar
28	Díaz ME, González L, Miquet JG, et al: Growth hormone modulation of EGF-induced PI3K-Akt pathway in mice liver. Cell Signal. 24:514–523. 2012. View Article : Google Scholar
29	Liu KW, Feng H, Bachoo R, et al: SHP-2/PTPN11 mediates glioma genesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J Clin Invest. 121:905–917. 2011. View Article : Google Scholar : PubMed/NCBI